Table 2.
Results of immunohistochemical staining in the primary tumours
| N | %* | |
|---|---|---|
| ER | ||
| Negative | 84 | 34.1 |
| Positive | 162 | 65.9 |
| PR | ||
| Negative | 93 | 37.1 |
| Positive | 158 | 62.9 |
| HER2 | ||
| Negative | 199 | 78.3 |
| Positive | 55 | 21.7 |
| E-cadherin | ||
| Negative | 24 | 10.4 |
| Positive | 206 | 89.6 |
| CK5/6 | ||
| Negative | 193 | 84.6 |
| Positive | 35 | 15.4 |
| CK14 | ||
| Negative | 213 | 90.6 |
| Positive | 22 | 9.4 |
| EGFR | ||
| Negative | 232 | 95.9 |
| Positive | 10 | 4.1 |
| TP53 | ||
| Negative | 163 | 69.1 |
| Positive | 73 | 30.9 |
| c-kit | ||
| Negative | 233 | 96.7 |
| Positive | 8 | 3.3 |
| Ki67 | ||
| Low | 37 | 19.3 |
| High | 155 | 80.7 |
ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor, CK cytokeratin, EGFR epidermal growth factor receptor
* Valid percentages